Last Chance To Influence Changes To NICE Methods & Processes In England
Executive Summary
Companies selling gene therapies and other high-cost, long-term treatments may be disappointed but unsurprised to learn that NICE will not immediately introduce any change to discount rates, which are used in health technology appraisals to better understand the long-term costs and benefits.
You may also be interested in...
England’s NICE To Find New Chief As Leng Announces Retirement
The top job at the National Institute for Health and Care Excellence has been described as one of the most challenging and potentially controversial roles in British public life.
England’s NICE To Find New Chief As Leng Announces Retirement
The top job at the National Institute for Health and Care Excellence has been described as one of the most challenging and potentially controversial roles in British public life.
Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.